Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01857206




Registration number
NCT01857206
Ethics application status
Date submitted
16/05/2013
Date registered
20/05/2013
Date last updated
5/12/2014

Titles & IDs
Public title
Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age
Scientific title
A Phase III, Observer Blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Chicken Eggs (Fluvirin®), in Healthy Children and Adolescents 4 to 17 Years of Age.
Secondary ID [1] 0 0
U1111-1139-9440
Secondary ID [2] 0 0
V58_31
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Influenza 0 0
Fever 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: TIVc - Subjects =4 to =17 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.

Active comparator: TIVf - Subjects =4 to =17 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number Of Subjects Reporting Solicited Local and Systemic Adverse Events and Other Indicators Of Reactogenicity After Any Vaccination.
Timepoint [1] 0 0
Day 1 to Day 7 after any vaccination
Primary outcome [2] 0 0
Number Of Subjects Reporting Unsolicited Adverse Events After Any Vaccination.
Timepoint [2] 0 0
Day 1 to Day49 for subjects aged =4 To =8 years not previously vaccinated. Day 1 to Day 38 for subjects aged =4 To =8 years previously vaccinated and all subjects aged =9 To =17 years.
Primary outcome [3] 0 0
Number Of Subjects Reporting Unsolicited Serious Adverse Events After Any Vaccination.
Timepoint [3] 0 0
Day 1 to Day 183 for previously vaccinated subjects and Day 213 for not-previously vaccinated subjects

Eligibility
Key inclusion criteria
- Healthy subjects 4-17 years of age
Minimum age
4 Years
Maximum age
17 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
* Subjects who are not healthy,
* Subjects who are pregnant or breast feeding,
* Subjects with a history of severe allergic reaction or allergic to any of the vaccine components.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/05/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/06/2014
Sample size
Target
Accrual to date
Final
2055
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
100, Novartis Investigational Site - Westmead
Recruitment hospital [2] 0 0
108, Novartis Investigational Site - Auchenflower
Recruitment hospital [3] 0 0
107, Novartis Investigational Site - Sherwood
Recruitment hospital [4] 0 0
104, Novartis Investigational Site - North Adelaide
Recruitment hospital [5] 0 0
103, Novartis Investigational Site - Carlton
Recruitment hospital [6] 0 0
105, Novartis Investigational Site - Subiaco
Recruitment postcode(s) [1] 0 0
2145 - Westmead
Recruitment postcode(s) [2] 0 0
4066 - Auchenflower
Recruitment postcode(s) [3] 0 0
4075 - Sherwood
Recruitment postcode(s) [4] 0 0
5006 - North Adelaide
Recruitment postcode(s) [5] 0 0
3010 - Carlton
Recruitment postcode(s) [6] 0 0
6008 - Subiaco
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Kansas
Country [4] 0 0
United States of America
State/province [4] 0 0
Nebraska
Country [5] 0 0
United States of America
State/province [5] 0 0
North Carolina
Country [6] 0 0
United States of America
State/province [6] 0 0
Ohio
Country [7] 0 0
United States of America
State/province [7] 0 0
Oklahoma
Country [8] 0 0
United States of America
State/province [8] 0 0
Rhode Island
Country [9] 0 0
United States of America
State/province [9] 0 0
South Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Tennessee
Country [11] 0 0
United States of America
State/province [11] 0 0
Utah
Country [12] 0 0
New Zealand
State/province [12] 0 0
Auckland
Country [13] 0 0
New Zealand
State/province [13] 0 0
Christchurch
Country [14] 0 0
Philippines
State/province [14] 0 0
Alabang
Country [15] 0 0
Philippines
State/province [15] 0 0
Ermita
Country [16] 0 0
Philippines
State/province [16] 0 0
Sampaloc
Country [17] 0 0
Thailand
State/province [17] 0 0
Muang
Country [18] 0 0
Thailand
State/province [18] 0 0
Rajathevi
Country [19] 0 0
Thailand
State/province [19] 0 0
Siriraj

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Vaccines
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Vaccines and Diagnostics
Address 0 0
Novartis Vaccines
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT01857206